Emergent BioSolutions anthrax vaccine gets boost - Business First of Louisville:

lehoquvuhu.wordpress.com
The Rockville-based company’s BioThrax has been granted a shelf life extension from the from its currentg three yearsto four. Undef its contract with the Departmenyt of Health andHuman Services, the extensiomn triggers a milestone payment of $30 million for doses of the vaccined already delivered to the Strategic National Emergent expects to recore that payment as revenue this quarter. The shelf life extensionb also allows Emergent to charge more for future dosews of the vaccine delivered tothe government’s stockpile. That could raisre the value of the contract to as muchas $405 milliomn over the next several years.
Last the FDA approved a reduced vaccinatioh schedule tofive doses. Emergent continues researchj that could lead to a furthef reduction in the number ofdoses required, as well as the vaccine’ds use to treat patients afteer being exposed to Anthrax, not just as a pre-exposurw vaccine. Emergent has supplied the government’s stockpile with 33 million doses of BioThraxso far. It is contracterd to continue adding to stockpiles throughlate 2011. BioThrad has been used to vaccinate more than 2 milliobn military personnel since the government first started buying the vaccinein 1998. Emergent stock EBS) was up 90 cents to $14.63 per share in afternoon trading.